CSAComputer Software Assurance

Computer Software Assurance (CSA) is the U.S. FDA’s draft guidance, issued in 2022, that reframes how manufacturers validate software used in production and quality systems. Rather than treating every function and every test script as equal, CSA channels rigor toward functions with the greatest potential to affect patient safety and product quality. It explicitly recognizes fit-for-purpose evidence, encourages critical thinking, and aims to reduce the accumulation of documentation that does not improve control of risk.

CSA is an evolution of Computer System Validation (CSV), not a repeal. The guidance confirms that electronic records and signatures requirements under 21 CFR Part 11 remain. It also preserves the obligation to validate automated processes, historically in 21 CFR 820.70(i), and aligns with the risk- and performance-based direction of FDA’s Quality Management System Regulation (QMSR). In short, CSA changes how you demonstrate assurance, not what you must assure.

In practice, CSA applies to non-product software that supports manufacturing and quality operations, such as manufacturing execution systems, laboratory systems, and quality management tools. It does not govern software contained in a medical device or standalone medical device software (which are addressed through premarket pathways and dedicated lifecycle standards). For production and quality system software, CSA promotes leveraging supplier documentation, unscripted or exploratory testing where appropriate, and automated evidence capture to strengthen assurance while removing low-value paperwork.

CSA sits within a durable regulatory framework. Electronic records and signatures under 21 CFR Part 11 continue to apply to any system that creates, modifies, maintains, or transmits regulated records. For device manufacturers, the obligation to validate software used in production and quality systems—long codified in 21 CFR Part 820—persists under the Quality Management System Regulation (QMSR), which aligns with ISO 13485. The upshot: the law still expects validated systems and trustworthy records; CSA clarifies that the approach should be proportional, science-based, and focused on risk.

The CSA draft guidance’s scope is production and quality system software. Examples include manufacturing execution, laboratory information, electronic batch/device history, environmental monitoring, label printing, and calibration/maintenance scheduling. It purposefully excludes software in a medical device and software as a medical device because those are subject to premarket submissions and domain-specific lifecycle standards. Where production or quality system software interconnects with device software lifecycles, organizations should ensure the respective regimes are clearly delineated and complementary.

Outside the U.S., authorities already emphasize risk-based validation. EU GMP Annex 11 requires validation commensurate with risk and complexity; PIC/S guidance expects documented, risk-based control of computerized systems; and ISO 13485 requires validation of software used in the quality management system. CSA harmonizes with these expectations by articulating how manufacturers can right-size testing and documentation while preserving traceability, data integrity, and change control obligations.

CSA operationalizes risk-based thinking through a structured decision process. Teams first define intended use and segregate functions by impact: those directly influencing product quality or patient safety warrant higher assurance, while ancillary or administrative features can be addressed with proportionate controls. This triage informs the testing strategy, the level of independence, and the necessary documentation. The approach favors critical thinking over rote templates, prioritizing evidence that demonstrates the system does what matters in the way it matters.

Evidence generation under CSA can include scripted testing where precision is essential and unscripted or exploratory testing where learning value is higher than stepwise repetition. Automated test logs, configuration export diffs, and audit trails can be directly relied on, reducing manual screenshots. Supplier development and verification artifacts may be accepted when qualified, thereby avoiding duplicative re-testing of unchanged, well-characterized components. Throughout, maintain traceability from intended use to risk to test rationale, and keep change control aligned with impact.

To communicate assurance coherently, organizations retain a requirements-to-test map and a succinct risk rationale. Many teams replace sprawling test scripts with focused charters tied to risk categories and acceptance criteria. Deviations are handled through concise, risk-aware assessments that explain what failed, why it matters, and how controls are restored. This keeps the validation narrative clear for assessors and efficient for practitioners.

CSA broadens acceptable evidence beyond traditional step-by-step scripts. It recognizes that credible assurance can come from multiple sources: risk-justified exploratory testing, challenge-based test charters, automated unit or integration test results, system audit trails, configuration export comparisons, access control verifications, and controlled supplier documentation. The art lies in selecting evidence that best demonstrates control of intended use risks, rather than amassing artifacts for their own sake.

Supplier evidence is particularly valuable. If a vendor maintains robust development controls, security practices, and regression testing, you can qualify and rely on those artifacts. Your local focus should then target configuration, integration, data flows, and usage scenarios unique to your process. This reduces rework and allows your validation team to invest where residual risk truly remains. Always document supplier qualification, scope of reliance, and how you verified that released versions match the attested build.

Electronic records and signatures do not change under CSA. Where Part 11 applies, retain definitive evidence of record integrity: validated audit trails, access and privilege management, time synchronization, and accurate, retrievable records. Keep approvals in a controlled quality system with versioned procedures and defined roles. Use concise deviation assessments grounded in risk when results differ from expectations, and ensure timely remediation and retesting where needed.

Practical documentation can be streamlined without losing rigor. Replace repetitious screenshots with secured test logs. Preserve test charters and outcomes as controlled quality records. Keep mapping artifacts slim by linking intended use, risk category, acceptance criteria, and the associated evidence. This makes audits faster and improves signal-to-noise for reviewers.

CSA does not relax statutory or regulatory requirements. Electronic records and signatures must still comply with 21 CFR Part 11 where applicable. Device manufacturers remain responsible for validating software used in production and quality systems under FDA’s QMSR, aligned with ISO 13485. Change control, configuration management, training, supplier oversight, and data integrity expectations remain central. The difference is that CSA encourages you to demonstrate these elements with targeted, risk-appropriate evidence instead of performative paperwork.

Data integrity remains a focal point across authorities. Maintain controls for attributable, legible, contemporaneous, original, and accurate (ALCOA) records, with secure audit trails and restricted privileges. Ensure time-stamped records, controlled user access, and validated backups. Where records are reviewed for release decisions, reviewers need clear, reliable data and a complete, unambiguous history of changes.

For regulated manufacturing, Part 11 technical and procedural controls should be demonstrably effective. This includes user authentication, electronic signatures bound to records, audit trail review practices, and procedures for incident management. Where the system interfaces with instruments or external services, establish data flow controls and verify that interfaces do not compromise record integrity. Finally, maintain periodic review to ensure controls remain effective as the system, process, and risk context evolve.

Teams moving from classic CSV to CSA sometimes overcorrect, mistaking “less paperwork” for “less validation.” CSA is about better validation. Another frequent error is failing to document the thinking that right-sized the work. Regulators expect a clear line of sight from intended use to risk rationale to the chosen testing and evidence. Without that, even efficient validation can appear arbitrary. Lastly, organizations occasionally conflate supplier qualification with unconditional reliance. CSA invites leverage of supplier artifacts, but only within a qualified, controlled scope.

The most robust CSA programs keep essentials visible: intended use statements, risk categorizations, acceptance criteria, test charters, concise outcomes, and deviations with risk-based dispositions. They also keep change management lively—capturing what changed, the risk impact, and the incremental assurance needed. These programs avoid large, stagnant traceability matrices in favor of lean, accurate mappings that are easy to review and maintain.

• Treating CSA as a waiver of Part 11 or device QMS obligations
• Dropping traceability instead of slimming it to a defensible, risk-based map
• Accepting supplier evidence without formal qualification or scope definition
• Overusing screenshots instead of controlled logs and audit trails
• Writing exploratory charters without explicit acceptance criteria or exit conditions
• Failing to update assurance after configuration or integration changes
• Confusing low procedural burden with low testing depth on high-impact functions

CSA and traditional CSV share the same goal: demonstrate that computerized systems are suitable for their intended use. CSV historically emphasized comprehensive scripted testing and extensive documentation. CSA emphasizes critical thinking, risk proportionate testing, and evidence that convincingly demonstrates control where it matters. In practice, many organizations adopt a hybrid: preserving familiar CSV constructs for high-impact functions while using CSA’s streamlined charters and supplier reliance for lower-impact areas.

GAMP 5 offers a lifecycle and categorization vocabulary that aligns naturally with CSA’s risk-based approach. EU GMP Annex 11 and PIC/S guidance require validation commensurate with risk and complexity—an expectation fully consistent with CSA. ISO 13485 requires validation of software used in the quality management system. ICH Q9 provides the overarching principles of quality risk management that underpin defensible, science-based decisions about what to test, how deeply, and why.

Device software lifecycle activities remain governed by standards such as IEC 62304 and by FDA premarket expectations. CSA does not substitute for those lifecycles. Instead, it complements them at the factory and quality system layer, especially for MES, LIMS, QMS, labeling, and data acquisition platforms. Organizations that document the interfaces between CSA-governed systems and device software lifecycles avoid duplication and ensure each regime covers its intended risks.

If your organization already uses GAMP-based methods, CSA adoption is typically an incremental shift: refine risk assessment, focus testing where it counts, and replace voluminous artifacts with higher-signal evidence. The result is shorter validation cycles and clearer, more persuasive audit narratives.

CSA’s principles resonate internationally because risk-based validation is widely expected. EU GMP Annex 11 emphasizes validation proportional to risk and complexity and clearly requires data integrity controls. EMA, national authorities, and PIC/S inspectorates routinely assess computerized systems for intended use, data integrity, and fitness for purpose. ISO 13485 requires that software used in the quality management system be validated commensurate with risk, which dovetails with CSA’s emphasis on critical thinking and targeted evidence.

Organizations with multinational operations can implement a unified, risk-based methodology that satisfies FDA’s CSA thinking and EU/PIC/S expectations simultaneously. Keep the core elements common: intended use statements, risk categorization, test strategy selection, lean traceability, supplier qualification, and change control. Then tune the presentation to local lexicons—calling out Annex 11 clauses for EU sites and Part 11/QMSR references for U.S. operations—without changing the underlying assurance logic.

Inspection experience shows that clarity of rationale and completeness of data integrity controls matter more than the specific template labels. Whether an assessor carries an FDA badge or a PIC/S inspector card, they will probe the same themes: what the system must do, how you know it does it reliably, how you manage changes, and how you protect records throughout their lifecycle. A single, coherent CSA-aligned narrative will answer these questions decisively.

Where corporate standards mention GAMP 5 or Annex 11 explicitly, it is straightforward to cross-reference CSA artifacts to the same control objectives. This avoids duplicative testing while ensuring auditors can find familiar anchors during reviews.

A successful CSA program begins with unambiguous intended use and ends with concise, auditable evidence. Treat the journey as a lifecycle, not a document push. Keep risk management front and center, and ensure cross-functional participation from process owners, quality, IT, and validation. Favor automation for repeatable checks and use supplier artifacts where qualified. Make traceability lightweight and accurate, linking risk categories to acceptance criteria, test charters, and outcomes.

Plan the assurance approach at the function level, not just the system level. Direct-impact functions tied to quality and safety deserve deeper, often scripted challenges and independence. Indirect-impact or administrative features can be covered with exploratory charters and focused confirmations. Always define exit criteria and document what was learned, not merely what was executed. Keep deviations proportionate and rooted in risk, explaining implications and mitigations clearly.

1. Inventory systems and define intended uses; segment functions by impact on product quality and patient safety
2. Perform a documented risk assessment and establish acceptance criteria tied to risk categories
3. Select test strategies (scripted, exploratory, automated) that best reveal defects that matter
4. Qualify suppliers and define the scope of reliance on vendor development and verification artifacts
5. Execute tests, capture controlled logs and audit trails, and record concise outcomes and deviations
6. Review evidence, disposition deviations by risk, and approve results within controlled procedures
7. Maintain change control, re-assess risk after changes, and monitor performance with periodic review

Throughout execution, streamline wisely: use controlled logs over screenshots, automated comparisons for configuration verification, and targeted charters for complex workflows. Keep your mapping artifact small but truthful, and maintain it throughout changes. This makes inspection preparation faster and ensures assurance activities can keep pace with the business.

Certain artifacts make CSA effective and sustainable across releases. A crisp intended use statement grounds the scope. A risk assessment that categorizes functions and justifies assurance depth creates a defensible backbone. Lean traceability connects intended use, risk categories, acceptance criteria, and the evidence you actually generated. Test charters define objectives, approaches, and exit conditions, and outcomes focus on what matters: failures found and confidence gained.

Automated evidence is a force multiplier. System audit trails, build and deployment logs, automated regression test reports, and configuration export diffs provide reliable, reviewable evidence without manual transcription. Supplier qualification packages capture how and why you rely on a vendor’s lifecycle controls and testing. When deviations occur, keep a compact, risk-based assessment that ties back to acceptance criteria. The dossier remains small but potent.

Finally, integrate CSA artifacts into your quality system. Procedures should explain how to choose assurance strategies, how to qualify suppliers, how to decide when scripted testing is necessary, and how to review audit trails. Training ensures teams can execute exploratory charters well and record outcomes clearly. Periodic reviews validate that the approach keeps pace with evolving risks, changes, and regulatory expectations.

With these tools and habits, CSA becomes a continuous practice rather than a one-time exercise, improving both compliance and speed.

V5 Ultimate operationalizes CSA while accommodating established CSV practices where needed. Our platform provides configurable workflows for intended use capture, risk categorization, supplier qualification, charter-based testing, and lean traceability. Automated evidence capture reduces manual screenshots by preserving secure logs, audit trails, and configuration diffs as controlled quality records. Where deep, scripted testing is warranted, V5 manages execution, approvals, and deviations in a single, auditable flow.

For regulated manufacturing contexts, V5’s modules help sustain enduring requirements: electronic records and signatures, access control, and review workflows that align with Part 11 expectations. Features for change control, deviation management, and periodic review ensure assurance keeps pace with updates. Our validation pack includes templates for risk-based charters, supplier reliance declarations, and concise mapping artifacts, alongside optional CSV-style traceability matrices for organizations maintaining mixed methods.

V5 connects validation to day-to-day operations. Integration with batch and device history, quality review, and exception handling centralizes the evidence chain from intended use to release decision. Dashboards make inspection preparation straightforward, surfacing acceptance criteria, test outcomes, deviations, and approvals. The result is faster, clearer assurance with less low-value paperwork and a stronger audit narrative.